Dexcom vs Freestyle Libre: Which CGM Is Right for You?

Comparing Dexcom G7 and FreeStyle Libre 3 on accuracy, wear time, cost, and alerts to help you choose the right CGM for your diabetes management.

Continuous glucose monitors (CGMs) measure blood sugar automatically, day and night, without fingersticks. The two leading options for people with diabetes are the Dexcom G7 and the FreeStyle Libre 3. Dexcom G7 offers real-time customizable alerts and a 10-day sensor, making it well-suited for type 1 diabetes and insulin pump users. FreeStyle Libre 3 costs significantly less, has a 14-day sensor, and suits type 2 diabetes and cost-conscious users.

• At a Glance: Dexcom G7 wears for 10 days with an 8-hour warmup; FreeStyle Libre 3 wears for 14 days with a 60-minute warmup.
• Accuracy: Dexcom G7 has an 8.7% MARD; FreeStyle Libre 3 has a 7.9% MARD (lower is more accurate).
• Cost without insurance: Dexcom G7 runs approximately $400 per month; FreeStyle Libre 3 runs approximately $150 per month.
• Both are FDA-approved, require no separate reader, and connect via Bluetooth directly to a smartphone app.
• Medicare, Medicaid, and most private insurance plans cover both CGMs for insulin-using patients.
• Both devices sync with Apple Health; Glucoly can import CGM readings via Apple Health to help you track glucose patterns over time.

What Is a CGM and How Does It Work?

A continuous glucose monitor is a small wearable device with a thin filament inserted just under the skin, typically on the arm or abdomen. The sensor measures glucose in the interstitial fluid every few minutes and transmits readings wirelessly to a smartphone app or dedicated receiver. Unlike a traditional blood glucose meter, a CGM captures a complete picture of glucose movement throughout the day and night, including rises after meals, overnight dips, and patterns that fingerstick checks would miss entirely.

CGMs display glucose in mg/dL or mmol/L depending on your region and device settings. They also show trend arrows indicating whether blood sugar is rising, falling, or stable, which is especially valuable when deciding on insulin doses or snacks.

Dexcom G7: Key Specs and Features

The Dexcom G7 is the current flagship sensor from Dexcom, FDA-cleared for use in both type 1 and type 2 diabetes. It integrates the transmitter directly into the sensor, making insertion a single step and the overall form factor the smallest in Dexcom's history.

• Warmup time: 8 hours from insertion to first reading.
• Sensor wear: 10 days per sensor, plus a 12-hour grace period.
• Accuracy: 8.7% mean absolute relative difference (MARD). Lower MARD indicates higher accuracy.
• Readings: sent automatically to the app every 5 minutes.
• Alerts: fully customizable high and low glucose alerts, urgent low alerts at 55 mg/dL (3.1 mmol/L), and predictive alerts that warn up to 20 minutes before a projected low.
• Connectivity: direct Bluetooth to iPhone and Android with no separate reader or receiver required.
• Integrations: compatible with major insulin pumps for closed-loop therapy, the Dexcom Clarity reporting app, and Apple Health.
• FDA status: cleared for non-adjunctive use, meaning you can make insulin dosing decisions based on the CGM reading alone without a confirmatory fingerstick.

FreeStyle Libre 3: Key Specs and Features

The FreeStyle Libre 3 from Abbott is the latest generation of the popular Libre line. It adds automatic Bluetooth streaming as a standard feature, so unlike earlier Libre models it does not require scanning the sensor to get a reading. The result is continuous, real-time glucose data in a sensor roughly the size of two stacked coins.

• Warmup time: 60 minutes from insertion to first reading, one of the fastest on the market.
• Sensor wear: 14 days per sensor.
• Accuracy: 7.9% MARD, slightly more accurate than the Dexcom G7 in clinical data.
• Readings: automatic, every minute, streamed continuously to the FreeStyle LibreLink app.
• Alerts: real-time high and low glucose alerts; customization options are more limited than Dexcom.
• Sensor size: the smallest CGM sensor available as of 2024.
• Connectivity: direct Bluetooth to iPhone and Android with no scanning or receiver needed.
• Integrations: Apple Health, the LibreView data platform, and select insulin delivery systems.
• FDA status: cleared for non-adjunctive insulin dosing decisions.

Dexcom G7 vs FreeStyle Libre 3: Side-by-Side Comparison

• Accuracy: FreeStyle Libre 3 edges out the Dexcom G7 with a 7.9% MARD versus 8.7%. Both are clinically validated for insulin dosing decisions.
• Warmup time: FreeStyle Libre 3 wins clearly at 60 minutes; Dexcom G7 requires an 8-hour warmup before the first reading.
• Wear time: FreeStyle Libre 3 lasts 14 days; Dexcom G7 lasts 10 days. Longer wear means fewer insertions and a lower per-day sensor cost.
• Alert customization: Dexcom G7 offers more granular settings, including customizable thresholds, time-of-day alert schedules, and predictive low alerts. FreeStyle Libre 3 provides simpler alert options.
• Cost without insurance: Dexcom G7 costs approximately $400 per month; FreeStyle Libre 3 costs approximately $150 per month.
• Insurance coverage: both are covered by Medicare Part B for eligible patients, Medicaid in most states, and most commercial plans for insulin-using patients.
• App ecosystem: Dexcom offers Clarity for detailed retrospective reporting and tighter insulin pump integration. Abbott offers LibreView and broader availability in some international markets.
• Pump integration: Dexcom G7 is compatible with more automated insulin delivery systems, including Tandem t:slim X2 and Omnipod 5, making it the standard sensor choice for closed-loop therapy.

Who Is Dexcom G7 Better For?

Dexcom G7 is generally the stronger choice for people who need real-time alerts and tight glucose management around the clock.

• Type 1 diabetes: Dexcom G7's customizable alerts and pump integrations make it the leading recommendation for T1D, particularly for those using an automated insulin delivery system.
• Insulin pump users: Dexcom is compatible with Tandem t:slim X2 and Omnipod 5 closed-loop systems. FreeStyle Libre 3 has more limited pump integration as of 2024.
• Active lifestyles with overnight hypoglycemia risk: customizable alert profiles allow different thresholds during sleep versus exercise, and the urgent low alert fires at 55 mg/dL (3.1 mmol/L).
• Those who need caregiver or family sharing: Dexcom Follow allows real-time glucose sharing with up to 10 followers, which is valuable for parents of children with T1D.
• People with hypoglycemia unawareness: predictive alerts warn up to 20 minutes before a projected low, adding an extra safety layer for those who do not reliably feel low symptoms.

Who Is FreeStyle Libre 3 Better For?

FreeStyle Libre 3 suits people who prioritize ease of use, lower cost, and longer wear time over advanced alert customization.

• Type 2 diabetes: many T2D patients do not require the advanced alert features of Dexcom and benefit more from the significantly lower out-of-pocket cost.
• Cost-conscious users without insurance coverage: at roughly $150 per month versus $400 per month, Libre 3 makes CGM more accessible for self-pay patients.
• Minimal setup preference: the 60-minute warmup and simple one-step insertion suit those who want a low-friction experience.
• People who prefer fewer sensor changes: the 14-day wear period means only two sensor changes per month, compared to three for Dexcom G7.
• International users: FreeStyle Libre has a wider global distribution network, particularly in Europe and parts of Asia where Dexcom availability may be limited.

Cost and Insurance Coverage

Out-of-pocket cost is one of the biggest factors in CGM choice, and the gap between the two devices is substantial.

• Dexcom G7 without insurance: approximately $400 per month for three 10-day sensors.
• FreeStyle Libre 3 without insurance: approximately $150 per month for two 14-day sensors.
• Medicare Part B: covers both devices for beneficiaries who use insulin, have an A1C above 7%, and meet frequency-of-testing requirements. Coverage requires a prescription.
• Medicaid: coverage varies by state. Most state Medicaid programs cover CGMs for insulin-using patients; check your individual state plan for specifics.
• Private insurance: most commercial plans cover CGMs for insulin-using T1D patients. T2D coverage varies and prior authorization is commonly required.
• Manufacturer savings programs: Dexcom and Abbott both offer savings cards and patient assistance programs for eligible uninsured or underinsured patients. See dexcom.com and freestylelibre.us for current offers.

How Glucoly Works with CGM Data

Glucoly is a blood sugar tracking app for iPhone and Android. It is not a CGM and does not replace one. However, because both the Dexcom G7 app and the FreeStyle LibreLink app write glucose readings to Apple Health, Glucoly can import that data automatically, giving you a unified view of your glucose history alongside other health metrics you log manually.

• Apple Health sync: both Dexcom and FreeStyle Libre apps write real-time glucose readings to Apple Health. Glucoly reads from Apple Health so your CGM data appears in Glucoly without any manual entry.
• Trend analysis: Glucoly displays 7, 14, 30, and 90-day trend windows across all logged metrics, helping you see how glucose patterns shift over time.
• Doctor-ready export: generate a PDF report of your glucose log to share with your care team, whether your data comes from a CGM or manual fingerstick readings.
• Multi-metric tracking: log blood pressure, weight, insulin doses, and medications alongside your CGM glucose data for a complete picture of your health.

This article is for general educational purposes and does not constitute medical advice. The choice of CGM should be made in consultation with your diabetes care team based on your individual clinical needs, insurance situation, and treatment goals. Always follow your doctor's guidance for insulin dosing and glucose targets.

Sources

• American Diabetes Association. Standards of Medical Care in Diabetes 2024. diabetes.org
• Centers for Disease Control and Prevention. Diabetes and Continuous Glucose Monitoring. cdc.gov/diabetes
• U.S. Food and Drug Administration. Continuous Glucose Monitoring Devices. fda.gov
• Dexcom. Dexcom G7 CGM System product information. dexcom.com
• Abbott. FreeStyle Libre 3 System product information. freestylelibre.us

← Back to all articles